title: Tuberculosis and cancer: parallels in host responses and therapeutic approaches?
abstract: Mycobacteria elicit two quite different immune responses. One is protective and is partly based on recognition and lysis of stressed, bacilli-laden cells expressing heat-shock proteins. The other suppresses this recognition and instead leads to indiscriminate necrosis of tissues containing mycobacteria (the Koch phenomenon). The type of response depends on the predominant T-cell maturation pathway, Th1 or Th2, which in turn is determined by priming by prior contact with environmental mycobacteria. Vaccination by BCG induces whichever response the recipient is primed to make, and this is a likely explanation of the variable efficacy of this vaccine in prevention of tuberculosis and therapy of cancer. Thus; BCG is a two-edged sword. We postulate that by using other mycobacterial preparations, such as killed Mycobacterium vaccae, it might be possible to suppress the indiscriminate necrosis and enhance Th1-regulated selective destruction of tumour cells.
authors.affiliation: Department of Microbiology, National Heart and Lung Institute, Royal Brompton Hospital, London.
authors.forename: J M
authors.initials: JM
authors.lastname: Grange
authors.forename: J L
authors.initials: JL
authors.lastname: Stanford
authors.forename: G A
authors.initials: GA
authors.lastname: Rook
mesh_terms: D001500:BCG Vaccine / Q000627:therapeutic use; D000939:Epitopes / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006360:Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology; D009336:Necrosis; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D018417:Th1 Cells / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine; D000939:Epitopes; D006684:HLA-DR Antigens; D006360:Heat-Shock Proteins